16 September 2026 note archive · Trial
Adaptive platform trial: golimumab in stage 1 (presymptomatic) T1D: review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected direct item relationships; shared class or background is insufficient.
Registry: NCT07683026. Endpoint reviewed: Progression to Dysglycemia (From randomization to confirmed dysglycemia or clinical diagnosis of T1D, approximately 6 years from the first participant enrolled.). Eligibility reviewed: Age 2 Years to 44 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Additional source access: Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes..